[go: up one dir, main page]

FR3083085B1 - Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide - Google Patents

Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide Download PDF

Info

Publication number
FR3083085B1
FR3083085B1 FR1855943A FR1855943A FR3083085B1 FR 3083085 B1 FR3083085 B1 FR 3083085B1 FR 1855943 A FR1855943 A FR 1855943A FR 1855943 A FR1855943 A FR 1855943A FR 3083085 B1 FR3083085 B1 FR 3083085B1
Authority
FR
France
Prior art keywords
amyline
aqueous solution
analogue
receptor agonist
polyaminoacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1855943A
Other languages
English (en)
Other versions
FR3083085A1 (fr
Inventor
You-Ping Chan
Alexandre Geissler
Romain Noel
Richard Charvet
Nicolas Laurent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1855943A priority Critical patent/FR3083085B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to MA051600A priority patent/MA51600A/fr
Priority to CN201880088465.3A priority patent/CN111683674A/zh
Priority to BR112020011479-0A priority patent/BR112020011479A2/pt
Priority to JP2020531134A priority patent/JP7637966B2/ja
Priority to EP18815677.2A priority patent/EP3740227A1/fr
Priority to EA202091201A priority patent/EA202091201A1/ru
Priority to AU2018380901A priority patent/AU2018380901A1/en
Priority to PCT/EP2018/083943 priority patent/WO2019110788A1/fr
Priority to IL275146A priority patent/IL275146B2/en
Priority to CA3084699A priority patent/CA3084699A1/fr
Priority to KR1020207019242A priority patent/KR20200106890A/ko
Priority to KR1020247039933A priority patent/KR20240171194A/ko
Priority to US16/213,865 priority patent/US11129877B2/en
Priority to SG11202005319PA priority patent/SG11202005319PA/en
Priority to MX2020005916A priority patent/MX2020005916A/es
Publication of FR3083085A1 publication Critical patent/FR3083085A1/fr
Priority to PH12020550804A priority patent/PH12020550804A1/en
Priority to SA520412138A priority patent/SA520412138B1/ar
Application granted granted Critical
Publication of FR3083085B1 publication Critical patent/FR3083085B1/fr
Priority to US17/404,735 priority patent/US12186373B2/en
Priority to US18/963,911 priority patent/US20250090638A1/en
Priority to AU2024278135A priority patent/AU2024278135A1/en
Priority to JP2024210838A priority patent/JP2025032188A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline ; b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, ledit co-polyaminoacide étant constitué d'unités glutamiques ou aspartiques et lesdits radicaux hydrophobes Hy étant de formule X suivante : c) caractérisée en ce que la composition ne comprend pas d'une insuline basale dont le point isoélectrique pI est compris entre 5,8 et 8,5. Elle concerne également une composition caractérisée en ce qu'elle comprend en outre une insuline prandiale.
FR1855943A 2017-12-07 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide Active FR3083085B1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR1855943A FR3083085B1 (fr) 2018-06-29 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US16/213,865 US11129877B2 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
BR112020011479-0A BR112020011479A2 (pt) 2017-12-07 2018-12-07 composições na forma de uma solução aquosa injetável caracterizada pelo fato de que compreende amilina, um agonista do receptor de amilina ou um análogo de amilina e um co-poliaminoácido
JP2020531134A JP7637966B2 (ja) 2017-12-07 2018-12-07 アミリン、アミリンアゴニスト受容体またはアミリン類似体およびコポリアミノ酸を含む注射水溶液の形態の組成物
EP18815677.2A EP3740227A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
EA202091201A EA202091201A1 (ru) 2018-06-29 2018-12-07 Композиции в форме инъецируемого водного раствора, содержащие амилин, агонист рецептора амилина или аналог амилина и сополиаминокислоту
AU2018380901A AU2018380901A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
CN201880088465.3A CN111683674A (zh) 2017-12-07 2018-12-07 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
IL275146A IL275146B2 (en) 2017-12-07 2018-12-07 Preparations in the form of an aqueous solution for injection comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
CA3084699A CA3084699A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
KR1020207019242A KR20200106890A (ko) 2017-12-07 2018-12-07 아밀린, 아밀린 작용제 수용체 또는 아밀린 유사체 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물
KR1020247039933A KR20240171194A (ko) 2017-12-07 2018-12-07 아밀린, 아밀린 작용제 수용체 또는 아밀린 유사체 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물
MA051600A MA51600A (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SG11202005319PA SG11202005319PA (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MX2020005916A MX2020005916A (es) 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
PCT/EP2018/083943 WO2019110788A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
PH12020550804A PH12020550804A1 (en) 2017-12-07 2020-06-04 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
SA520412138A SA520412138B1 (ar) 2017-12-07 2020-06-07 تركيبات في صورة محلول مائي قابل للحقن يشتمل على أميلين، ومستقبل مساعد أميلين أو نظير أميلين وحمض بولي أمينو مشترك
US17/404,735 US12186373B2 (en) 2017-12-07 2021-08-17 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
US18/963,911 US20250090638A1 (en) 2017-12-07 2024-11-29 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
AU2024278135A AU2024278135A1 (en) 2017-12-07 2024-12-04 Compositions In The Form Of An Injectable Aqueous Solution Comprising Amylin, An Amylin Receptor Agonist Or An Amylin Analog And A Copolyamino Acid
JP2024210838A JP2025032188A (ja) 2017-12-07 2024-12-04 アミリン、アミリンアゴニスト受容体またはアミリン類似体およびコポリアミノ酸を含む注射水溶液の形態の組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1855943 2018-06-29
FR1855943A FR3083085B1 (fr) 2018-06-29 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Publications (2)

Publication Number Publication Date
FR3083085A1 FR3083085A1 (fr) 2020-01-03
FR3083085B1 true FR3083085B1 (fr) 2020-10-02

Family

ID=65031316

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1855943A Active FR3083085B1 (fr) 2017-12-07 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Country Status (2)

Country Link
EA (1) EA202091201A1 (fr)
FR (1) FR3083085B1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
SK31496A3 (en) 1993-09-07 1998-06-03 Amylin Pharmaceuticals Inc Use of amylin, amylin agonists and amylin antagonists for regulating gastrointestinal motility
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
WO2007104786A1 (fr) 2006-03-15 2007-09-20 Novo Nordisk A/S Melanges d'amyline et d'insuline
ES2785056T3 (es) 2007-07-02 2020-10-05 Hoffmann La Roche Un dispositivo para la administración de fármacos
BR112014010275A2 (pt) 2011-10-31 2017-04-18 Xeris Pharmaceuticals Inc formulações para tratamento de diabetes
CN104114155B (zh) * 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液

Also Published As

Publication number Publication date
FR3083085A1 (fr) 2020-01-03
EA202091201A1 (ru) 2020-09-29

Similar Documents

Publication Publication Date Title
SG11201810937WA (en) Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
SA520412141B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على إنسولين قاعدي واحد على الأقل يتراوح الخاص به بين 5.8 و8.5 وحمض بولي أمينو مشترك حامل لشحنات pi كربوكسيلات وشقوق غير قابلة للذوبان في الماء
BRPI0606142A2 (pt) agonistas de pyy e usos dos mesmos
CY1112353T1 (el) Παραγωγα μεταστινης και χρηση αυτων
MA40571A (fr) Composition comprenant un melange d'extraits vegetaux ou un melange de molecules contenues dans ces vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
EA200800233A1 (ru) Композиция иммуноконьюгата
SA520411871B1 (ar) شكل مختلف من جسم مضاد وشكل إسوي يتسم بنشاط حيوي منخفض
MA51127A (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
AR078325A1 (es) Formulacion acuosa de n-(cianofenil) pirazolcarboxamida
MA51597A (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
BR112013006087A2 (pt) lubrificantes de transportador incluindo emulsões e métodos para empregá-los
DE602004012289D1 (de) Bioaktive peptide, die durch enzymatische hydrolyse aus den proteinen von eiweiss gewonnen werden
UA104490C2 (uk) Рефлектор з кріпильним пристроєм для ошийників для тварин
FR3061023B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074682B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MA39386B1 (fr) Utilisation d'une composition bitumineuse comme liant de collage
FR3031039B1 (fr) Composition apaisante pour animaux comprenant au moins un acide gras et de la nepetalactone
FR3074680B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2008051862A3 (fr) Compositions renforçant l'immunité comprenant du bêta-1,3/1,6-d-glucane et utilisations de celles-ci
MA37672A1 (fr) Formulation d'agoniste des récepteurs à la somatostatine
PE20211387A1 (es) Compuestos organicos
FR3079414B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3074422B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200103

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

GC Lien (pledge) constituted

Effective date: 20210525

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

RG Lien (pledge) cancelled

Effective date: 20231011

PLFP Fee payment

Year of fee payment: 7